Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer

Sponsors and Collaborators

Eisai Inc.
Quintiles

Contact
Mark Shelton
[email protected]

Principal Investigator
Mark Shelton, Quintiles

Continue Reading

ClinicalTrials.gov Identifier
NCT01126749